Emerson has made an equity investment in Fluxa, whose Process & Knowledge Management software manages product and process specifications throughout the drug development lifecycle. The investment will build on Emerson’s life sciences capabilities and help Fluxa expand its technology development and commercial pipeline. Fluxa was founded in 2017 by Sudheesh Narayanan, Suraj Pai and John Miller. The company is based in Glendale, CA. The terms of the investment were not disclosed.
The emergence of COVID-19 has sparked innovation in the life sciences manufacturing development process, as a cycle that previously required over eight years was completed in less than 18 months through expedited research and development and automation technologies, including those offered by Emerson. This acceleration and its possibilities for the industry have made technology transfer – critical to move quickly from R&D to production – a main priority for life sciences companies.